Jonathan Wygant, the Chief Accounting Officer at Veracyte, Inc., has filed a report detailing a transaction involving the withholding of shares of common stock to meet tax obligations. This transaction, which took place on October 28, 2026, underscores the financial activities of the company and reflects Wygant's adherence to regulatory requirements.

Wygant's recent filing is significant as it provides insight into the financial maneuvers of Veracyte, a company engaged in the medical laboratories sector. The transaction involved the withholding of 1,306 shares at a price of $50.31 per share, which was necessary to satisfy tax withholding obligations associated with the vesting of restricted stock units.

Background

Veracyte, Inc. is a company incorporated in Delaware, primarily operating in the medical laboratories sector, classified under the SIC code 8071. The company is known for its innovative diagnostic solutions that aid in the diagnosis of various medical conditions. The most recent filings indicate that Wygant has been actively involved in the company's financial reporting, with multiple Form 4 submissions over recent months.

What the Filing Says

The filing states, "Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on October 28, 2026 and does not represent a sale." This clarification is crucial for investors and stakeholders monitoring the company's financial health.

Impact

This transaction may primarily affect Veracyte's shareholders and potential investors, as it reflects the company's ongoing financial activities and compliance with tax obligations. Such transactions can influence perceptions of the company's financial stability and governance practices.

What's Next

The filing does not say what happens next.